Amgen launches an AbbVie Humira biosimilar in the US
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Funds sell $44bn in semiconductors on AI concerns
Amgen (AMGN) Announces Amjevita now Available in the US
January 31, 2023 6:03 AM ESTAmgen (NASDAQ: AMGN) today announced AMJEVITA (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.2,3
"With today's announcement, AMJEVITA is the first U.S. biosimilar to Humira®, a medicine used by more than a million patients living with certain serious inflammatory diseases," said Murdo... More
Amgen (AMGN) PT Lowered to $260 at UBS
January 30, 2023 8:51 AM ESTUBS analyst Colin Bristow lowered the price target on Amgen (NASDAQ: AMGN) to $260.00 (from $271.00) while maintaining a Neutral rating.... More
Drugmaker Amgen lays off 300 U.S. employees
January 30, 2023 7:56 AM EST(Reuters) -Drugmaker Amgen Inc said on Monday that it let go about 300 U.S. employees or about 1.2% of its total workforce, citing recent organizational changes to its commercial team.
The company had about 24,200 staff members in over 50 countries, as of December 31, 2021, according to its latest annual regulatory... More
